Clearmind reports no serious adverse events in CMND-100 dose trial
Go back to Clearmind reports no serious adverse events in CMND-100 dose trial| (NASDAQ: CMND) | Delayed: 1.07 +0.04 (3.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.03 | 52 Week High | $ | |||
| Open | $1.07 | 52 Week Low | $ | |||
| Day High | $1.11 | P/E | N/A | |||
| Day Low | $1.00 | EPS | $ | |||
| Volume | 288,030 | |||||

